Nonalcoholic Steatohepatitis (NASH) is a more serious form of non-alcoholic fatty liver disease (NAFLD) . Due to its lack of symptoms, NASH is often unrecognized and under diagnosed.  The highest prevalence of NASH is in those who are obese and/or have type 2 diabetes, hypertension and other cardiovascular disease.  Patients with NASH can develop fibrosis and ultimately cirrhosis of the liver potentially leading to liver cancer or requiring a liver transplant. 

Currently there is no approved medication to treat NASH.

If you have been diagnosed with NASH, you may be eligible to participate in a landmark study investigating a medication that could potentially reduce the steatosis or excessive fat from the liver.

To qualify you must:

• Be between ages 18-70
• Have type 2 diabetes (HbA1c 7 - 10.5)
• Be taking metformin only for diabetes
• Have liver fat >/=8% by MRI-PDFF

Qualified participants will  receive:

• Investigational study medication and study-related medical care at no cost
• Reimbursement for time and travel 

Health Insurance is not required to participate.

Call 416--844-2990 or complete the short form.